<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828057</url>
  </required_header>
  <id_info>
    <org_study_id>TW-VISIONARY Study</org_study_id>
    <nct_id>NCT04828057</nct_id>
  </id_info>
  <brief_title>Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting</brief_title>
  <official_title>Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharmaceutical (Taiwan) Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharmaceutical (Taiwan) Co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in&#xD;
      controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP)&#xD;
      from baseline to after 6 months of treatment from initiation, in patients with open angle&#xD;
      glaucoma (OAG) or ocular hypertension (OHT), who do not respond sufficiently to initial&#xD;
      topical treatment, in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in&#xD;
      controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP)&#xD;
      from baseline to after 6 months of treatment from initiation, in patients with open angle&#xD;
      glaucoma (OAG) or ocular hypertension (OHT), who do not respond sufficiently to initial&#xD;
      topical treatment, in routine clinical practice.&#xD;
&#xD;
      This study will include adults with open angle glaucoma or ocular hypertension, who received&#xD;
      their first Tafluprost / Timolol prescription at baseline, even if Tafluprost / Timolol was&#xD;
      not continued after the first prescription. In addition, patients must have their IOP&#xD;
      recorded within 7 days before their first prescription of Tafluprost / Timolol, in order to&#xD;
      be eligible for this study. Only those who provide informed consent will be included.&#xD;
&#xD;
      At the time of a scheduled clinic visit, eligible patients will be invited to participate in&#xD;
      the study and willing patients will be requested to sign an informed consent form. Once&#xD;
      informed consent is obtained, the patient is included in the study and relevant data will be&#xD;
      recorded during routine clinical visits. Participation in this study is entirely voluntary;&#xD;
      any patient may withdraw consent to participate in this study at any time. The withdrawn&#xD;
      patient's data will not be analyzed in this study and the number of patients who withdrew&#xD;
      consent will appear in the final study report.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of intraocular pressure (IOP)</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>The primary endpoint will be assessed for the whole patient group and separately in specific subgroups according to their last glaucoma treatments before initiating Tafluprost / Timolol. Classification of prior therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in intra-ocular pressure (IOP) from baseline to after 4 and 12 weeks</measure>
    <time_frame>from baseline to after 4 and 12 weeks of treatment from initiation</time_frame>
    <description>Mean change in intra-ocular pressure (IOP) from baseline to after 4 and 12 weeks of treatment from initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders at 12 weeks, defined as change from baseline IOP of 20% or more</measure>
    <time_frame>12 weeks post initiation</time_frame>
    <description>Proportion of responders at 12 weeks,defined as change from baseline IOP of 20% or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical signs with Tafluprost / Timolol</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Change in conjunctival hyperaemia distribution by severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the evaluation of subjective symptoms with Tafluprost / Timolol. Difference in distribution by severity. Severity categorized as none, mild, moderate, severe.</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Dry eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effectiveness (IOP-development) of Tafluprost / Timolol by the physician as measured by change in distribution by severity</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>Better than prior medication&#xD;
Same as prior medication&#xD;
Worse than prior medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical signs during therapy with Tafluprost / Timolol by the physician as measured by change in distribution by severity</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>Better than prior medication&#xD;
Same as prior medication&#xD;
Worse than prior medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tolerability of Tafluprost / Timolol by the Patient as measured by change in distribution by severity</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>Very good&#xD;
Good&#xD;
Satisfactorily&#xD;
Poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician assessment of patient compliance compared to previous therapy</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>Better&#xD;
Equal&#xD;
Worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant therapy for glaucoma</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>Record concomitant therapy from baseline to 6 months post initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical signs with Tafluprost / Timolol</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Change in corneal fluorescein staining (CFS) distribution by severity. Optional</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical signs with Tafluprost / Timolol</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Mean change in Visual acuity (VA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical signs with Tafluprost / Timolol</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Mean change in Schirmer's test. Optional</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical signs with Tafluprost / Timolol</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Mean change in tear break up time (TBUT). Optional</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the evaluation of subjective symptoms with Tafluprost / Timolol. Difference in distribution by severity. Severity categorized as none, mild, moderate, severe.</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Irritation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the evaluation of subjective symptoms with Tafluprost / Timolol. Difference in distribution by severity. Severity categorized as none, mild, moderate, severe.</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Itching eyes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the evaluation of subjective symptoms with Tafluprost / Timolol. Difference in distribution by severity. Severity categorized as none, mild, moderate, severe.</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Foreign body sensation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the evaluation of subjective symptoms with Tafluprost / Timolol. Difference in distribution by severity. Severity categorized as none, mild, moderate, severe.</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Eye pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the evaluation of subjective symptoms with Tafluprost / Timolol. Difference in distribution by severity. Severity categorized as none, mild, moderate, severe.</measure>
    <time_frame>6 months post initiation</time_frame>
    <description>o Other</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Ocular Surface Disease</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafluprost, timolol maleate</intervention_name>
    <description>Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.</description>
    <other_name>latanoprost</other_name>
    <other_name>tafluprost</other_name>
    <other_name>bimatoprost</other_name>
    <other_name>travoprost</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for the current study is all eligible patients who received at least&#xD;
        one prescription of Tafluprost / Timolol in Taiwan; however, the sample population will be&#xD;
        limited to eligible patients in the clinics included in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent obtained before any study-related activities (study-related&#xD;
             activities are any procedure related to extraction of data according to the protocol)&#xD;
&#xD;
          -  According to the approved indications of Tafluprost / Timolol as indicated in the SPC&#xD;
&#xD;
               -  Male or female patients â‰¥20 years of age at time of informed consent&#xD;
&#xD;
               -  Diagnosis of open angle glaucoma or ocular hypertension&#xD;
&#xD;
               -  Insufficient IOP control with a monotherapy utilizing topical prostaglandin&#xD;
                  analogues, necessitating the use of a combination therapy according to the&#xD;
                  judgement of the treating ophthalmologist&#xD;
&#xD;
               -  Patient judged by their physician to benefit from preservative free eye drops&#xD;
&#xD;
          -  Not used Tafluprost / Timolol before&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient pregnant or nursing&#xD;
&#xD;
          -  Pregnancy planned in the following 6 months&#xD;
&#xD;
          -  Presence of contraindications as listed in the SPC&#xD;
&#xD;
          -  Any ophthalmologic surgery within 6 months prior to the study&#xD;
&#xD;
          -  Participation in any other investigational study within 30 days prior to enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-wen Su</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei-wen Su</last_name>
    <phone>+886-975-362-646</phone>
    <email>vickysuweiwen@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang-Geng Medical Foundation Linkou Chang-Geng Memorial Hospital</name>
      <address>
        <city>Taoyuan city</city>
        <zip>333012</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su Wei-Wen</last_name>
      <phone>+886-975-362-646</phone>
      <email>vickysuweiwen@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tafluprost</keyword>
  <keyword>Tapcom-s</keyword>
  <keyword>switching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

